Freelance Pharmaceutical And Biotech Writer
Nick Paul Taylor is a Freelance Pharmaceutical and Biotech Writer. He specializes in various aspects of medicine and healthcare, focusing on pharmaceuticals, healthcare technology, medical specialties, and medical technology. His work has been featured in prominent publications such as Healthcare Dive, BioPharma Dive, and Yahoo Finance, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nick Paul Taylor's articles are focused on the healthcare and pharmaceutical industry, particularly highlighting data-driven content. His coverage centers around medical technology, pharmaceutical companies, clinical trials, drug development, and biotechnology.
Given his focus on citing data and press releases, Nick is likely to be interested in pitches that provide newsworthy statistics or insights from credible sources within the healthcare and pharmaceutical sectors. He may also respond well to pitches related to government announcements impacting these industries.
As he does not have a specific geographic focus mentioned but covers global pharmaceutical news extensively, consider providing international perspectives or insights when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nick Paul Taylor
Medtronic has backed CoreMap to address a critical unmet need in atrial fibrillation treatment.
By: Nick, Paul Taylor
Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
By: Nick, Paul Taylor
A phase 3 trial of Novo Nordisk's ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company's portfolio.
By: Nick, Paul Taylor
A phase 2 trial of Merck & Co.'s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover.
By: Nick, Paul Taylor
Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera.
The University of Oxford spinout will soon launch the AI tool, which research suggests could help assess heart attack risk in patients who don’t have obstructive coronary artery disease.
Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker's chances of delivering a return on its investment.
By: Nick, Paul Taylor
Context Therapeutics has stopped development of the bispecific T-cell engager (TCE) CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change or drop certain claims about its blockbuster medicine Dupixent.
By: Nick, Paul Taylor
The software business needs “a different investment level” to quickly realize its potential, Solventum's CEO said.
